ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies
Status:
Recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
The study is a first-in-human, Phase I study to assess the safety of ProAgio in participants
with advanced solid tumor malignancies including pancreatic cancer.